“The Emerging Therapeutic Target” explores nutritional therapies to positively affect clinical outcomes in patients with multiple chronic diseases
SAN CLEMENTE, CA (October 9, 2007)— Metagenics, Inc., a leading developer of medical foods and nutraceuticals sold exclusively through healthcare practitioners, today announced the launch of its revolutionary new seminar Series, “The Emerging Therapeutic Target—Improving Therapeutic Outcomes by Treating the Intersection of Osteoporosis, Cardiovascular Disease, Type 2 Diabetes, and Arthritis.” Presenting the seminars will be Jeffrey S. Bland, PhD, FACN, Metagenics Chief Science Officer and a leading authority on the effects of dietary factors on genetic expression, or nutrigenomics. The seminars will run from January through April 2008, and will take place in 14 major cities throughout the United States as well as Toronto, Canada.
Western healthcare has traditionally focused on the diagnosis as the sine qua non, or essential condition, of treatment. However, in the United States alone, over 60 million patients with chronic disease present with multiple symptoms. For these patients, this medical paradigm often includes a variety of interventions that treat each diagnosis differently, leading to a phenomena known as polypharmacy—the administration of an excessive number of medications.
During the seminar, Dr. Bland will explore the clinical and basic science leading to the understanding of an intersection, or underlying physiological mechanism, associated with chronic conditions such as osteoporosis, cardiovascular diseases, type 2 diabetes, arthritis and other inflammatory conditions, and dementia. By addressing the intersection, or root cause, of disease in patients with multiple chronic conditions, healthcare providers can achieve more effective clinical outcomes.
“Addressing the therapeutic target is a revolutionary clinical approach to managing the imbalanced physiology associated with many chronic diseases,” said Dr. Bland. “The takeaways from this seminar will help clinicians expand their therapy options and achieve better patient outcomes.”
Key clinical takeaways include:
Exploring the emerging research on the interaction between genetic potential and environmental factors
Identifying the therapeutic target, or intersection of multiple chronic conditions, to improve patient outcomes
Mastering cutting-edge, clinical applications to address underlying physiological mechanisms associated with chronic disease
The seminars are open to all licensed healthcare practitioners and cost $149 USD (early bird) or $169 (regular). Lunch is included. Pre-registration is required. Those interested in attending should contact Metagenics Educational Programs at 800-692-9400 or for more information visit online at http://www.metagenics.com/seminars.
About Jeffrey Bland, PhD, FACN
Jeffrey S. Bland, PhD is internationally respected for his ground-breaking work in nutrigenomics and nutritional biochemistry, applied clinical nutrition, and functional medicine. Dr. Bland received his PhD from the University of Oregon in 1971, and served as a professor of chemistry at the University of Puget Sound in Tacoma, Washington, for 13 years. He also served as Senior Research Scientist at the Linus Pauling Institute of Science and Medicine, and directed the Bellevue-Redmond Medical Laboratory in Washington State. He is the author of more than 150 papers and five books on nutrition and its relationship to health and disease. For the past 15 years, Dr. Bland has produced Functional Medicine Update (FMU), a monthly audio tape in which he reviews and synthesizes the medical literature and interviews notable clinicians and researchers.
About Metagenics, Inc.
Metagenics is a life sciences company and leading developer and manufacturer of science-based medical foods and nutraceuticals sold to healthcare practitioners worldwide. It is headquartered in San Clemente, CA, with manufacturing and research facilities located in Gig Harbor, WA, including the MetaProteomics® Nutrigenomics Research Center and the Functional Medicine Research CenterSM for human clinical research. Metagenics holds multiple proprietary formula patents and produces more than 400 research-based products to optimize health. The company demonstrates its commitment to purity and quality through its certifications for Good Manufacturing Practices ( GMP) from the NPA, NSF International, and TGA. For more information, please visit www.metagenics.com.